Cytoskeleton derangement in brain of patients with Down Syndrome, Alzheimer’s disease and Pick’s disease

  • D. Pollak
  • N. Cairns
  • G. Lubec
Part of the Journal of Neural Transmission Supplement 67 book series (NEURAL SUPPL, volume 67)


Although cytoskeleton derangement has been reported in brain of patients with neurodegenerative disorders, basic information on integral constituents forming this network including stoichiometric composition is missing. It was therefore the aim of the study to qualitatively and quantitatively evaluate individual proteins of the three major classes representing the cytoskeleton of human brain.

Cytoskeleton proteins β-actin (βA), alpha-actinin (Act), tubulin beta-III (βIII), microtubule associated protein 1 (MAP1), neurofilaments NF-L, NF-M and NF-H and neuron specific enolase (NSE), a marker for neuronal density, were determined by immunoblotting. Brain samples (frontal cortex) of controls (CO), patients with Down Syndrome (DS), Alzheimer’s disease (AD) and Pick’s disease (PD) were used for the study.

In DS brain βIII, NF-H and NF-M, in AD brain NF-M and NF-H and in PD brain NF-L, NF-M and NF-H were significantly reduced. Stoichiometry of cytoskeleton proteins in control brain revealed the following relations:

βA:Act:βIII:MAP1:NF-L:NF-M:NF-H = 1.0:0.8:3.8:2.4:3.2:2.2.

This stoichiometrical ratios were aberrant in DS, AD and PD with the main outcome that ratios of members of the neurocytoskeleton (βIII, NF’s) in relation to βA were remarkably decreased. This finding confirms data of decreased neuronal density using NSE in DS and AD.

We propose stoichiometry of cytoskeleton elements in normal brain and confirm and extend knowledge on cytoskeleton defects in neurodegenerative diseases. The finding of significantly decreased individual elements may well lead to or represent disassembly of the neurocytoskeleton observed in neurodegenerative diseases.


Down Syndrome Neuron Specific Enolase Neuronal Density Cytoskeletal Element Cytoskeleton Protein 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Avila J, Dominguez J, Diaz-Nido J (1994) Regulation of microtubule dynamics by microtubule-associated protein expression and phosphorylation during neuronal development. Int J Dev Biol 38 (1): 13–25PubMedGoogle Scholar
  2. Bajo M, Yoo BC, Cairns N, Gratzer M, Lubec G (2001) Neurofilament proteins NF-L, NF-M, NF-H in brains of patients with Down syndrome and Alzheimer’s disease. Amino Acids 21: 293–301PubMedCrossRefGoogle Scholar
  3. Bloch W, Fan Y, Han J, Xue S, Schoeneberg T, Ji G, Lu ZJ, Walther M, Faessler R, Hescheler J, Addicks K, Fleischmann BK (2001) Disruption of cytoskeletal integrity impairs G1-mediated signaling due to displacement of G1 proteins. J Cell Biol 154 (4): 753–761PubMedCrossRefGoogle Scholar
  4. Cambazio V, Gonzales M, Maccioni RB (1995) DMAP-85: a tau-like protein from Drosophila larvae. J Neurochem 64 (3): 1288–1297CrossRefGoogle Scholar
  5. Coffey RL, Purich DL (1995) Non-cooperative binding of the MAP-2 microtubulebinding region to microtubules. J Biol Chem 270 (3): 1035–1040PubMedCrossRefGoogle Scholar
  6. Dickson DW (1998) Pick’s disease: a modern approach. Brain Pathol 8: 339–354PubMedCrossRefGoogle Scholar
  7. Doering LC (1993) Probing modifications of the neuronal cytoskeleton. Mol Neurobiol 7 (3–4): 265–291PubMedCrossRefGoogle Scholar
  8. Dong D, Xu ZS, Chevrier MR, Cotter RJ, Cleveland DW, Hart GW (1993) Glycosylation of mammalian neurofilaments. J Biol Chem 268 (22): 16679–16687PubMedGoogle Scholar
  9. Fountoulakis M, Hardmeier R, Hoeger H, Lubec G (2001) Postmortem changes in the level of brain proteins. Exp Neurol 167 (1): 86–94PubMedCrossRefGoogle Scholar
  10. Frappier T, Regnouf F, Pradel LA (1987) Binding of brain spectrin to the 70-kDa neurofilament subunit protein. Eur J Biochem 169 (3): 651–657PubMedCrossRefGoogle Scholar
  11. Gulesserian T, Kim SH, Fountoulakis M, Lubec G (2002) Aberrant expression of centractin and capping proteins, integral constituents of the dynactin complex, in fetal Down syndrome brain. Biochem Biophys Res Commun 291: 62–67PubMedCrossRefGoogle Scholar
  12. Ishikawa R, Kagami O, Hayashi C, Kohama K (1992) The binding of nonmuscle caldesmon from brain to microtububles. Regulations by calcium calmodulin and cdc2 kinase. Biochemistry 33 (41): 12463–12470Google Scholar
  13. Julien JP, Mushynski WF (1998) Neurofilaments in health and disease. Prog Nucl Acid Res Mol Biol 6: 1–23CrossRefGoogle Scholar
  14. Kaech S, Parmar H, Roelandse M, Bornmann C, Matus A (2001) Cytoskeletal microdifferentiation: a mechanism for organizing morphological plasticity in dendrites. Proc Natl Acad Sci USA 98 (13): 7086–7092PubMedCrossRefGoogle Scholar
  15. Kamal A, Stokin GB, Yang Z, Xia CH, Goldstein LS (2000) Axonal transport of amyloid precursor protein is medaited by direct binding to the light chain subunit of kinesinI. Neuron 28 (2): 449–459PubMedCrossRefGoogle Scholar
  16. Kirsch J, Langosch D, Prior P, Littauer UZ, Kohama K (1991) The 93-kDa glycine receptor-associated protein binds to tubulin. J Biol Chem 266 (33): 22242–22245PubMedGoogle Scholar
  17. Kittur S, Hoh J, Endo H, Tourtelotte W, Weeks BS, Markesbery W, Adler W (1994) Cytoskeletal neurofilament gene expression in brain tissue from Alzheimer’s disease patients. Decrease in NF-L and NF-M message. J Geriat Psychiatry Neurol 7 (3): 153–158Google Scholar
  18. La Monte B, Wallace KE, Holloway BA, Shelly SS, Ascano J, Tokito M, Van Winkle T, Howland DS, Holzbaur ELF (2002) Dysruption of dynein/dynactin inhibits axonal transport in motor neurons causing late-onset progressive degeneration. Neuron 34: 715–727CrossRefGoogle Scholar
  19. Lim RW, Halpain S (2000) Regulated association of microtubule-associated protein 2 (MAP2) with Src and Grb2: evidence for MAP2 as a scaffolding protein. J Biol Chem 275 (27): 20578–20587PubMedCrossRefGoogle Scholar
  20. Lubec B, Weitzdoerfer R, Fountoulakis M (2001) Manifold reduction of moesin in fetal Down syndrome brain. Biochem Biophys Res Comm 286 (5): 1191–4PubMedCrossRefGoogle Scholar
  21. Sanchez C, Diaz-Nido J, Avila J (2000) Phosphorylation of microtubule-associated protein 2 (MAP2) and its relevance for the regulation of neuronal cytoskeleton function. Prog Neurobiol 61 (2): 133–168PubMedCrossRefGoogle Scholar
  22. Scott D, Smith KE, O’Brien BJ, Angelides KJ (1985) Characterization of mammalian neurofilament triplet proteins. Subunit stoichiometry and morphology of native and reconstituted filaments. J Biol Chem 260 (19): 10736–10747PubMedGoogle Scholar
  23. Shim KS, Lubec G (2002) Drebrin, a dendritic spine protein, is manifold decreased in brains of patients with Alzheimer’s disease and Down syndrome. Neurosci Lett 324 (3): 209–212PubMedCrossRefGoogle Scholar
  24. Siegel GJ, Agranoff BW, Albers RW, Fisher SK, Uhler MD (1999) Basic neurochemistry, molecular, cellular and medical aspects, 6th edn. Lippincott Williams & Wilkins, PhiladelphiaGoogle Scholar
  25. Sihak RK (1998) Brain beta-spectrin phosphorylation: phosphate analysis and identification of threonin as a heparin-sensitive protein kinase phosphorylation site. J Neurochem 71 (5): 2220–2228CrossRefGoogle Scholar
  26. Steiner JP, Ling E, Bennet V (1987) Nearest neighbor analysis for brain synapsin I. Evidence from in vitro reassociation for association with membrane protein(s) and the Mr = 68.0000 neurofilament subunit. J Biol Chem 262 (2): 905–914PubMedGoogle Scholar
  27. Terasaki AG, Morikawa K, Suzuki H, Oshima H, Ohashi K (2002) Characterisation of the arp2/3 complex in chicken tissues. Cell Struct Funct 27 (5): 383–391PubMedCrossRefGoogle Scholar
  28. Weitzdoerfer R, Dierssen M, Fountoulakis M, Lubec G (2001) Fetal life in Down syndrome starts with normal neuronal density but impaired dendritic spines and synaptosomal structure. J Neural Transm [Suppl] 61: 59–70Google Scholar
  29. Weitzdoerfer R, Fountoulakis M, Lubec G (2002) Reduction of actin-related protein complex 2/3 in fetal Down Syndrome brain. Biochem Biophys Res Commun 293 (2): 836–841PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2003

Authors and Affiliations

  • D. Pollak
    • 1
  • N. Cairns
    • 2
  • G. Lubec
    • 1
    • 3
  1. 1.Department of Pediatrics, Division Basic SciencesUniversity of ViennaViennaAustria
  2. 2.Department of NeuropathologyKing’s CollegeLondonUK
  3. 3.CChem, FRSC (UK), Department of PediatricsUniversity of ViennaViennaAustria

Personalised recommendations